X4 Pharmaceuticals
XFOR
57 hedge funds and large institutions have $102M invested in X4 Pharmaceuticals in 2020 Q2 according to their latest regulatory filings, with 17 funds opening new positions, 17 increasing their positions, 12 reducing their positions, and 10 closing their positions.
70% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 10
42% more repeat investments, than reductions
Existing positions increased: 17 | Existing positions reduced: 12
14% more funds holding
Funds holding: 50 → 57 (+7)
0.05% less ownership
Funds ownership: 2.33% → 2.28% (-0.05%)
10% less capital invested
Capital invested by funds: $113M → $102M (-$11.1M)
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LGM
Logos Global Management
San Francisco,
California
|
+$1.45M |
| 2 |
State Street
Boston,
Massachusetts
|
+$1.33M |
| 3 |
BlackRock
New York
|
+$890K |
| 4 |
ZIM
Zacks Investment Management
Chicago,
Illinois
|
+$695K |
| 5 |
Northern Trust
Chicago,
Illinois
|
+$524K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NMC
NEA Management Company
Timonium,
Maryland
|
-$3.33M |
| 2 |
SFM
Sphera Funds Management
Tel Aviv,
Israel
|
-$2.81M |
| 3 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$1.53M |
| 4 |
BI
BVF Inc
San Francisco,
California
|
-$1.47M |
| 5 |
Alyeska Investment Group
Chicago,
Illinois
|
-$999K |
XFOR Hedge Fund Activity: Q2 2020 in Review
57 of the 4,877 institutional investors tracked by Wall St. Rank reported a position in X4 Pharmaceuticals (XFOR) for Q2 2020, worth a combined $102M — down 9.9% from $113M a quarter earlier.
Buyers outnumbered sellers: 17 funds opened new XFOR positions and 10 closed out — a net gain of 7 holders — while 17 added to existing stakes and 12 trimmed.
The largest buyer was Logos Global Management, opening a new position worth an estimated $1.45M. The largest seller was NEA Management Company, exiting entirely with an estimated $3.33M sold.
- 57 institutional investors held X4 Pharmaceuticals (XFOR) as of Q2 2020, up from 50 in Q1 2020.
- Funds reported $102M of X4 Pharmaceuticals stock for Q2 2020, down 9.9% quarter-over-quarter.
- 17 funds opened new X4 Pharmaceuticals positions in Q2 2020 and 10 closed out, a net change of +7 holders.
- The largest X4 Pharmaceuticals buyer in Q2 2020 was Logos Global Management, an estimated $1.45M added.
- The largest X4 Pharmaceuticals seller in Q2 2020 was NEA Management Company, an estimated $3.33M sold.
Based on aggregated 13F filings for Q2 2020.